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We would like to thank Stroobandt, S. and Stroobandt, R. for showing interest in our
paper [1] and for sharing their concerns regarding COVID-19 vaccine safety in pregnant
women [2]. Although not being the main focus of our article, it is a key component of
COVID-19 vaccine acceptance in the pregnant woman population.
Both authors are warning the readership of Viruses about the safety of COVID-19
mRNA vaccines, suggesting an interpretation error in the results of Shimabukuro et al.’s
study which was considered as the first evidence of the safety of the COVID-19 vaccine
in pregnancy [3]. Stroobandt, S. and Stroobandt, R.’s interpretation leads to an 82% risk
of spontaneous abortion (104 spontaneous abortions for 127 participants exposed to the
first dose of the COVID-19 vaccine during the first trimester and who have completed their
pregnancy) instead of the 12.6% calculated by Shimabukuro and colleagues (104 sponta-
neous abortions for 807 participants with a pregnancy outcome at the time of analysis).
As we totally disagree with their interpretation of these data, we would like to take the
opportunity to respond to their letter.
Shimabukuro et al. decided to include in their analysis all women exposed to a
COVID-19 mRNA vaccine during pregnancy and who had the chance to complete their
pregnancy (i.e., live birth, spontaneous abortion, stillbirth, induced abortion and ectopic
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pregnancy). This conservative approach has led to a larger contribution to the study
population of both patients with exposure occurring later in pregnancy and those with a
short-term outcome, such as spontaneous abortion, as the available time to follow up was
short. To our understanding, this study population might not have fairly represented the
population at risk for spontaneous abortion and might have led to a selection of women
ending with a spontaneous abortion. Spontaneous abortion incidence rates are sensitive
to gestational age at enrollment as the risk decreases over gestation, with later enrollees
carrying a lower risk, or no risk of the outcome as mentioned by Stroobandt, S. and
Stroobandt, R. Thus, a dedicated analysis estimating the rate of spontaneous abortion by
considering all women vaccinated during the first trimester who either had or were at
risk of having a spontaneous abortion (i.e., beyond 20 weeks of amenorrhea at the time
of the analysis), even if still with an ongoing pregnancy, would probably have provided
a fairer estimate. With the information available in the paper by Shimabukuro et al.,
the spontaneous abortion risk would have probably been around 10% (104 spontaneous
abortion for 1132 women vaccinated during the first trimester), which is even lower than
the previously published estimate.
In our opinion, the debated data, along with other published data [4,5] show very
reassuring results when evaluating the SARS-CoV-2 vaccination safety among pregnant
women to date. This is of paramount importance as pregnant women are considered a
vulnerable population for SARS-CoV-2 infection [6].
Conflicts of Interest: The authors declare no conflict of interest.
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